Lilly Obesity Pill: As Effective as GLP-1 Injections?
- Eli Lilly's experimental oral medication, orforglipron, is demonstrating effectiveness in weight loss and blood sugar control for individuals with type 2 diabetes.
- The trial involved 559 patients with type 2 diabetes,testing three different dosages of orforglipron against a placebo over 40 weeks.The results indicated that all three doses effectively lowered...
- Kenneth Custer, president of cariometabolic health at Eli Lilly, emphasized the consistency of the pill's efficacy, safety, and tolerability with top-tier injectable GLP-1s.
Could Eli Lilly’s oral medication, orforglipron, be as effective as injectable GLP-1 drugs for weight loss and blood sugar control? New clinical trial data suggests this daily pill shows promise in rivaling the results of popular injectables like Ozempic. Discover statistically significant weight loss results for participants with type 2 diabetes and find out more about the consistent efficacy shown. This pivotal research, published in the New England Journal of Medicine, could reshape treatment approaches, providing advantages for cost, and easy storage.A News Directory 3 update offers insights into this potential game-changer in diabetes management. Learn about the plan for regulatory approval, and the potential impact for patients across areas with limited storage. Discover what’s next for this exciting development.
Orforglipron’s Role in Weight loss: Eli Lilly’s Oral Drug Shows Promise
Eli Lilly’s experimental oral medication, orforglipron, is demonstrating effectiveness in weight loss and blood sugar control for individuals with type 2 diabetes. Phase 3 trial data, presented at the American diabetes Association meeting and published in the New England Journal of Medicine, suggests the daily pill could rival the results of injectable GLP-1 drugs like Ozempic.
The trial involved 559 patients with type 2 diabetes,testing three different dosages of orforglipron against a placebo over 40 weeks.The results indicated that all three doses effectively lowered blood sugar levels.The 12 mg and 36 mg doses also produced significant reductions in body weight. Participants on the highest dose experienced an average weight loss of 7.9%, or 16 pounds.
Kenneth Custer, president of cariometabolic health at Eli Lilly, emphasized the consistency of the pill’s efficacy, safety, and tolerability with top-tier injectable GLP-1s. “What we see is that the efficacy, safety, and tolerability are really consistent with the very best injectable GLP-1s,” custer said. “We think this is a big deal.”
Eli Lilly plans to seek regulatory approval for orforglipron for weight management by the end of 2025 and for type 2 diabetes treatment in 2026. The company is also conducting a longer study to assess the drug’s long-term effects on overweight and obese individuals.
Participants in the trial took orforglipron once daily without dietary restrictions. The dosage was gradually increased over four-week intervals, a strategy similar to that used with current GLP-1 drugs to minimize side effects. Common side effects included diarrhea, nausea, indigestion, and constipation, mirroring those associated with other GLP-1 medications.Discontinuation rates due to side effects ranged from 4% to 8% across the different dosage groups, compared to 1% in the placebo group.
Priya Jaisinghani, a diabetes and obesity medicine specialist at NYU Langone, noted the potential for improved adherence due to the drug’s advantages. “With orforglipron offering additional advantages such as the elimination of strict pre-dosing requirements,potential lower cost,and easier storage,it will be crucial to see whether these features lead to even greater adherence,” Jaisinghani said. “Like most chronic therapies,GLP-1s are most effective when used consistently,so a formulation that encourages long-term use could have a meaningful impact on patient outcomes.”
What’s next
If approved, orforglipron could provide a more accessible and perhaps more affordable option for weight management and diabetes treatment, especially in regions lacking the infrastructure for cold-chain storage required by injectable GLP-1 drugs.